Nida Wongchaisuwat, Alessia Amato, Andrew E Lamborn, Paul Yang, Lesley Everett, Mark E Pennesi
{"title":"视网膜色素变性 GTPase 调节器相关视网膜病变与基因治疗。","authors":"Nida Wongchaisuwat, Alessia Amato, Andrew E Lamborn, Paul Yang, Lesley Everett, Mark E Pennesi","doi":"10.4103/sjopt.sjopt_168_23","DOIUrl":null,"url":null,"abstract":"<p><p>Retinitis pigmentosa GTPase regulator <i>(RPGR)</i>-related retinopathy is a retinal dystrophy inherited in a X-linked recessive manner that typically causes progressive visual loss starting in childhood with severe visual impairment by the fourth decade of life. It manifests as an early onset and severe form of retinitis pigmentosa. There are currently no effective treatments for <i>RPGR</i>-related retinopathy; however, there are multiple clinical trials in progress exploring gene augmentation therapy aimed at slowing down or halting the progression of disease and possibly restoring visual function. This review focuses on the molecular biology, clinical manifestations, and the recent progress of gene therapy clinical trials.</p>","PeriodicalId":46810,"journal":{"name":"Saudi Journal of Ophthalmology","volume":"37 4","pages":"276-286"},"PeriodicalIF":0.6000,"publicationDate":"2023-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752277/pdf/","citationCount":"0","resultStr":"{\"title\":\"Retinitis pigmentosa GTPase regulator-related retinopathy and gene therapy.\",\"authors\":\"Nida Wongchaisuwat, Alessia Amato, Andrew E Lamborn, Paul Yang, Lesley Everett, Mark E Pennesi\",\"doi\":\"10.4103/sjopt.sjopt_168_23\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Retinitis pigmentosa GTPase regulator <i>(RPGR)</i>-related retinopathy is a retinal dystrophy inherited in a X-linked recessive manner that typically causes progressive visual loss starting in childhood with severe visual impairment by the fourth decade of life. It manifests as an early onset and severe form of retinitis pigmentosa. There are currently no effective treatments for <i>RPGR</i>-related retinopathy; however, there are multiple clinical trials in progress exploring gene augmentation therapy aimed at slowing down or halting the progression of disease and possibly restoring visual function. This review focuses on the molecular biology, clinical manifestations, and the recent progress of gene therapy clinical trials.</p>\",\"PeriodicalId\":46810,\"journal\":{\"name\":\"Saudi Journal of Ophthalmology\",\"volume\":\"37 4\",\"pages\":\"276-286\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2023-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10752277/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Saudi Journal of Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/sjopt.sjopt_168_23\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Saudi Journal of Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/sjopt.sjopt_168_23","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
视网膜色素变性 GTPase 调节器(RPGR)相关视网膜病变是一种以 X 连锁隐性方式遗传的视网膜营养不良症,通常会从儿童期开始导致进行性视力丧失,到第四个十年时出现严重的视力损伤。它表现为早发且严重的视网膜色素变性。目前,RPGR 相关视网膜病变还没有有效的治疗方法;不过,有多项临床试验正在进行中,旨在探索基因增强疗法,以减缓或阻止疾病的发展,并在可能的情况下恢复视功能。本综述将重点介绍基因治疗临床试验的分子生物学、临床表现和最新进展。
Retinitis pigmentosa GTPase regulator-related retinopathy and gene therapy.
Retinitis pigmentosa GTPase regulator (RPGR)-related retinopathy is a retinal dystrophy inherited in a X-linked recessive manner that typically causes progressive visual loss starting in childhood with severe visual impairment by the fourth decade of life. It manifests as an early onset and severe form of retinitis pigmentosa. There are currently no effective treatments for RPGR-related retinopathy; however, there are multiple clinical trials in progress exploring gene augmentation therapy aimed at slowing down or halting the progression of disease and possibly restoring visual function. This review focuses on the molecular biology, clinical manifestations, and the recent progress of gene therapy clinical trials.
期刊介绍:
Saudi Journal of Ophthalmology is an English language, peer-reviewed scholarly publication in the area of ophthalmology. Saudi Journal of Ophthalmology publishes original papers, clinical studies, reviews and case reports. Saudi Journal of Ophthalmology is the official publication of the Saudi Ophthalmological Society and is published by King Saud University in collaboration with Elsevier and is edited by an international group of eminent researchers.